

Corporate News

Darwin AG with very positive third quarter results 2025

München, 05.12.2025

Darwin AG (ISIN DE000A3C35W0) today published its voluntary quarterly report for the period ending September 30, 2025.

The positive revenue trend from the first half of the year continues. In the first three quarters of 2025, the Group generated approximately €41.4 million in revenue, roughly 60% more than in the entire year of 2024. The Group's pre-tax profit for the first three quarters, amounting to approximately €4.6 million, benefited from a significantly higher pre-tax profit of approximately €2.5 million in the third quarter compared to the previous quarters.

"This exceptionally positive quarterly result demonstrates that we at the Darwin Group are on the right track," commented CEO Dr. Daniel Wallerstorfer. *"Looking ahead, we anticipate further revenue growth with increasing operating margins."* the company founder continued.

The quarterly report is available for download at www.darwin-biotech.com/de/financial-reports.

Background

The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analyses carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

Contact:

Darwin AG

Brienner Str. 7
80333 München

Tel: +49 89 / 20 500 450
investor.relations@darwin-biotech.com